Effectiveness and Safety of 1L PEG-ASC Preparation for Colonoscopy in Patients With Inflammatory Bowel Diseases

Aims The effectiveness of bowel cleansing is a key element for a quality colonoscopy, especially in patients with inflammatory bowel diseases (IBD), both for assessment of mucosal healing and for detection of pre-neoplastic lesions during surveillance.

Recently, a 1L polyethylene glycol plus ascorbate solution (Plenvu; Norgine, Harefield, UK) has been introduced on the evidence of three RCTs. Nevertheless, the effectiveness and safety of this preparation in IBD patients have not been assessed. This study aims to evaluate the effectiveness and safety of Plenvu in patients with IBD compared to controls.

Methods We retrospectively reviewed a prospective cohort of 411 in- and out-patients aged >18 years performing a colonoscopy after preparation with Plenvu, consecutively enrolled from November 2019 to February 2020 in 5 Italian centres.

Results Overall, 185/411 (45 %) were IBD patients (51.4 % with Ulcerative Colitis and 48.6 % with Crohn’s Disease), and 226/411 (55 %) controls. A significantly higher bowel cleansing success was achieved in IBD patients (92.9 % vs 85.4 %, p=0.02), with a similar high-quality cleansing of the right colon (39.1 % vs 40.5 %, p=0.7) compared to controls.

At logistic multiple regression only split preparation (OR=3.97, 95 % CI=1.08-14.53; P = 0.037) was independently associated with overall bowel cleansing success in IBD patients.

The number of patients with any mild to moderate treatment-related adverse events (AEs) was lower in the IBD compared to the control group (8.6 % vs 22.1 %, p<0.001).

Days of low-fiber diet (OR=2.19, 95 % CI=1.24-3.85; P = 0.006), longer duration of disease (OR=1.09, 95 % CI=1.02-1.16; P = 0.005), and diabetes (OR=5.83, 95 % CI=1.28-26.6; P = 0.023) were independently associated with incidence of AEs in IBD patients at logistic multiple regression.

Conclusions Results from this study support the high effectiveness and the safety of Plenvu in IBD patients. The higher cleansing success rates achieved with this preparation may, therefore, contribute to a more accurate definition of endoscopic outcomes in patients with IBD.

Citation: Maida M, Morreale GC, Sferrazza S etal. eP291 EFFECTIVENESS AND SAFETY OF 1L PEG-ASC PREPARATION FOR COLONOSCOPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES. Endoscopy 2021; 53: S194.

Publication History

Article published online:
19 March 2021